World Drug Safety Congress Americas 2017
Drug Safety remains a key topic as the regulatory landscape evolves to meet the demands of scientific innovation. In our ninth year, we will be covering the latest technological developments in drug safety including integration, data source, signal detection, safety analytics and regulation.
Since its launch in 2008, this conference has stood out as a unique forum for the industry. Not only are we discussing the latest advances, practical sessions will provide you the tools to tackle day-to-day challenges. Topics under discussion in 2017 include the use of social media to support risk management practices, applying fresh thinking to signal management challenges, outsourcing vs. in-house clinical data management and achieving collaboration between pharmacovigilance and technology.
2017 is set to be the best year yet, with even more pharma representation than ever before. Companies already confirmed to attend include
AbbVie, Alexion Pharmaceuticals, Amgen, AstraZeneca, Baxalta, Bristol Myers Squibb, Genentech, Genzyme, GlaxoSmithKline, Horizon Pharma, Merck, Novartis, Pfizer, Sanofi,
. That's not all! The regulatory, CRO, technology and consultancy communities will also be in attendance.
World Drug Safety Congress Americas is the meeting place of global pioneers who are shaping the pharmacovigilance industry.
We look forward to welcoming you to Philadelphia in May.